[A case of Parkinson's disease with neuroleptic malignant syndrome induced by paroxetine].
We present a first case of Parkinson's disease with neuroleptic malignant syndrome by Paroxetine, one of the selective serotonin reuptake inhibitor (SSRI). The patient was a 73-year-old woman who had been diagnosed as Parkinson's disease for one and half year. The severity of her disease was categorized as Hoehn & Yahr 2nd degree and she had taken 0.25 mg/day of Pramipexole. Four days after the addition of 10 mg/day of Paroxetine for the treatment of her depression, she developed consciousness disturbance, severe muscular rigidity, tremor, fever, hyperhidrosis, incontinence and elevated serum creatine kinase level. According to diagnostic criteria, she was diagnosed as neuroleptic malignant syndrome probably induced by Paroxetine. Her clinical symptoms and laboratory data were improved seven days after intravenous drip infusion. We should recognize that SSRI could induce neuroleptic malignant syndrome in patients with Parkinson's disease.
Hamada
Yukihiro
Y
Department of Neurology, Kinki University School of Medicine.
Miyamoto
Katsuichi
K
Inatsugi
Yohei
Y
Suzuki
Hidekazu
H
Kusunoki
Susumu
S
D000368:Aged; D003863:Depression / Q000188:drug therapy; D005260:Female; D006801:Humans; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D010300:Parkinson Disease / Q000188:drug therapy* / Q000523:psychology; D017374:Paroxetine / Q000009:adverse effects*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*
D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors